FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979624432> ?p ?o ?g. }

• W2979624432 abstract "Abstract Clonal cytogenetic aberrations of the Philadelphia chromosome (Ph) positive hematopoiesis have been associated with the natural evolution of CML to advanced disease. Clonal aberrations of Ph negative metaphases have been described after treatment with interferon alpha or imatinib in a minority of patients (pts) with cytogenetic response. Conflicting data suggest selection of preexisting clones vs. induction of aneuploidy by tyrosine kinase inhibitors. The prognostic impact of aberrations in the Ph negative hematopoiesis for the individual pts remains to be determined. Dasatinib is a multitargeted agent inhibiting both ABL and SRC tyrosine kinases. The efficacy and safety of dasatinib has been demonstrated in phase I and II studies in pts with Ph positive CML after failure of imatinib therapy. We sought to evaluate the effect of dasatinib on Ph positive clones with additional cytogenetic aberrations and the frequency of novel aberrations in Ph positive and Ph negative metaphases during dasatinib therapy. 71 pts (40 m, 31 f) with Ph positive CML after failure of imatinib therapy have been evaluated. Median age was 58 years (range, 28–78), median time from diagnosis 73 months (range, 14–231). Pts were in chronic phase (CP, n=50), accelerated phase (AP, n=6), myeloid (n=8) or lymphoid (n=7) blast crisis (BC). Pretreatment consisted of imatinib (n=71), hydroxyurea (n=48), interferon alpha (n=49), cytosine arabinoside (n=11) and nilotinib (n=2). Dasatinib therapy was commenced at a dose of 100–140 mg/day, median duration of dasatinib therapy was 9 months, (range, 1–16). Prior to dasatinib therapy, 22 pts (31%) demonstrated additional chromosomal aberrations in the Ph positive clone indicating BCR-ABL independent mechanisms of resistance. Of these, 8 pts were in CP (16%), 5 in AP (83%), and 9 in BC (60%). In 35 pts (49%), BCR-ABL mutations associated indicating a BCR-ABL dependent mechanism of resistance were observed. 9 pts (13%) showed both clonal evolution and BCR-ABL mutations. Two pts (3%) had trisomy 8 as an aberration of the Ph negative clone at baseline. During dasatinib therapy, 33 pts (46%) achieved major cytogenetic remission, 26 (37%) being complete. From pts with clonal evolution, 3 (14%) achieved a major with 2 (9%) complete cytogenetic remissions. Novel aberrations of the Ph positive clone appeared during dasatinib therapy in 6 pts (8%), aberrations of the Ph negative clone in 3 pts (4%). In total, 5/71 pts (7%) showed clonal aberrations of Ph negative metaphases after consecutive imatinib/dasatinib therapies. None of these pts had morphological indications for secondary neoplastic changes, like myelodysplasia or acute leukemia. In conclusion, dasatinib was efficacious in pts with clonal cytogenetic aberrations as a marker of BCR-ABL independent imatinib resistance. However, cytogenetic response was delayed compared to pts without additional aberrations. Preexisting clonal aberrations of the Ph negative hematopoiesis were uncovered by a simultaneous gradual elimination of the Ph positive clone. In addition, a minority of pts demonstrated novel aberrations in Ph negative cells. The prognostic significance of aneuploidy of the Ph negative hematopoiesis remains to be evaluated by long term observation." @default.
• W2979624432 created "2019-10-18" @default.
• W2979624432 creator A5007614326 @default.
• W2979624432 creator A5015469407 @default.
• W2979624432 creator A5016147985 @default.
• W2979624432 creator A5029290022 @default.
• W2979624432 creator A5034129066 @default.
• W2979624432 creator A5035964802 @default.
• W2979624432 creator A5039428434 @default.
• W2979624432 creator A5044098380 @default.
• W2979624432 creator A5056061790 @default.
• W2979624432 creator A5064255883 @default.
• W2979624432 date "2006-11-01" @default.
• W2979624432 modified "2023-10-01" @default.
• W2979624432 title "Dynamics of Cytogenetic Aberrations in Philadelphia Chromosome Positive and Negative Hematopoiesis during Dasatinib Therapy of Chronic Myeloid Leukemia Patients after Imatinib Failure." @default.
• W2979624432 cites W1978514731 @default.
• W2979624432 cites W1994309500 @default.
• W2979624432 cites W1997991070 @default.
• W2979624432 cites W2003973314 @default.
• W2979624432 cites W2006917576 @default.
• W2979624432 cites W2011474502 @default.
• W2979624432 cites W2019031643 @default.
• W2979624432 cites W2037798465 @default.
• W2979624432 cites W2062578749 @default.
• W2979624432 cites W2070683532 @default.
• W2979624432 cites W2076239625 @default.
• W2979624432 cites W2080125373 @default.
• W2979624432 cites W2092606584 @default.
• W2979624432 cites W2094403971 @default.
• W2979624432 cites W2109169220 @default.
• W2979624432 cites W2339359539 @default.
• W2979624432 cites W2559141012 @default.
• W2979624432 cites W327786117 @default.
• W2979624432 doi "https://doi.org/10.1182/blood.v108.11.2114.2114" @default.
• W2979624432 hasPublicationYear "2006" @default.
• W2979624432 type Work @default.
• W2979624432 sameAs 2979624432 @default.
• W2979624432 citedByCount "0" @default.
• W2979624432 crossrefType "journal-article" @default.
• W2979624432 hasAuthorship W2979624432A5007614326 @default.
• W2979624432 hasAuthorship W2979624432A5015469407 @default.
• W2979624432 hasAuthorship W2979624432A5016147985 @default.
• W2979624432 hasAuthorship W2979624432A5029290022 @default.
• W2979624432 hasAuthorship W2979624432A5034129066 @default.
• W2979624432 hasAuthorship W2979624432A5035964802 @default.
• W2979624432 hasAuthorship W2979624432A5039428434 @default.
• W2979624432 hasAuthorship W2979624432A5044098380 @default.
• W2979624432 hasAuthorship W2979624432A5056061790 @default.
• W2979624432 hasAuthorship W2979624432A5064255883 @default.
• W2979624432 hasConcept C104317684 @default.
• W2979624432 hasConcept C113968399 @default.
• W2979624432 hasConcept C121608353 @default.
• W2979624432 hasConcept C126322002 @default.
• W2979624432 hasConcept C138626823 @default.
• W2979624432 hasConcept C143998085 @default.
• W2979624432 hasConcept C203014093 @default.
• W2979624432 hasConcept C2777583451 @default.
• W2979624432 hasConcept C2778729363 @default.
• W2979624432 hasConcept C2778904597 @default.
• W2979624432 hasConcept C2779282312 @default.
• W2979624432 hasConcept C2779536868 @default.
• W2979624432 hasConcept C3019892230 @default.
• W2979624432 hasConcept C502942594 @default.
• W2979624432 hasConcept C54355233 @default.
• W2979624432 hasConcept C71924100 @default.
• W2979624432 hasConcept C86803240 @default.
• W2979624432 hasConceptScore W2979624432C104317684 @default.
• W2979624432 hasConceptScore W2979624432C113968399 @default.
• W2979624432 hasConceptScore W2979624432C121608353 @default.
• W2979624432 hasConceptScore W2979624432C126322002 @default.
• W2979624432 hasConceptScore W2979624432C138626823 @default.
• W2979624432 hasConceptScore W2979624432C143998085 @default.
• W2979624432 hasConceptScore W2979624432C203014093 @default.
• W2979624432 hasConceptScore W2979624432C2777583451 @default.
• W2979624432 hasConceptScore W2979624432C2778729363 @default.
• W2979624432 hasConceptScore W2979624432C2778904597 @default.
• W2979624432 hasConceptScore W2979624432C2779282312 @default.
• W2979624432 hasConceptScore W2979624432C2779536868 @default.
• W2979624432 hasConceptScore W2979624432C3019892230 @default.
• W2979624432 hasConceptScore W2979624432C502942594 @default.
• W2979624432 hasConceptScore W2979624432C54355233 @default.
• W2979624432 hasConceptScore W2979624432C71924100 @default.
• W2979624432 hasConceptScore W2979624432C86803240 @default.
• W2979624432 hasLocation W29796244321 @default.
• W2979624432 hasOpenAccess W2979624432 @default.
• W2979624432 hasPrimaryLocation W29796244321 @default.
• W2979624432 hasRelatedWork W1554937972 @default.
• W2979624432 hasRelatedWork W17970610 @default.
• W2979624432 hasRelatedWork W2019199342 @default.
• W2979624432 hasRelatedWork W2025935458 @default.
• W2979624432 hasRelatedWork W2027064263 @default.
• W2979624432 hasRelatedWork W2053212028 @default.
• W2979624432 hasRelatedWork W2107946380 @default.
• W2979624432 hasRelatedWork W2120868842 @default.
• W2979624432 hasRelatedWork W3143018572 @default.
• W2979624432 hasRelatedWork W4288062214 @default.
• W2979624432 isParatext "false" @default.
• W2979624432 isRetracted "false" @default.
• W2979624432 magId "2979624432" @default.
• W2979624432 workType "article" @default.